A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours

Investigational New Drugs

Volumn 25, Issue 3, 2007, Pages 217-225

  Baetz, Tara ^a   Eisenhauer, Elizabeth ^b   Siu, Lillian ^c   MacLean, Martha ^c   Doppler, Karen ^a   Walsh, Wendy ^b   Fisher, Bryn ^b   Khan, Azhar Z ^d   De Alwis, Dinesh P ^d   Weitzman, A ^d   Brail, Leslie H ^d   Moore, Malcolm ^c  

^a Cancer Centre of Southeastern Ontario   (Canada)

^b Queen's Cancer Research Institute   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Clinical trial; Irinotecan; LY293111; Phase I

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIEMETIC AGENT; ATROPINE; IRINOTECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY TRACT TUMOR; BLADDER TUMOR; BLURRED VISION; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLON TUMOR; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG WITHDRAWAL; DYSARTHRIA; FATIGUE; FEMALE; GALLBLADDER TUMOR; GRANULOCYTOPENIA; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MERKEL CELL TUMOR; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY TUMOR; PANCREAS TUMOR; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; STOMACH TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 34248637001     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9021-8     Document Type: Article

References (23)

1. Tang DG, Chen YQ, Honn KV (1996) Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 93:5241-5246
2. Crooks SW, Stockley RA (1998) Leukotriene B4. Int J Biochem Cell Biol 30(2):173-178
3. Hagmann W (1997) Lipoxygenase in human tumor cells. Pathol Oncol Res 3(2):83-88
4. Reich R, Martin GR (1996) Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 51(1):1-17
5. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B (1996) The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta 1300(3):240-246
6. Mann EL, Spiro JD, Chen LL, Kreutzer DL (1994) Phospholipid metabolite expression by head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 120(7):763-769
7. Jackson, WT, Froelich LL, Boyd RJ, Schrementi JP, Saussy DL, Schultz RM, Sawyer JS, Sofia MJ, Herron DK, Goodson T, Snyder DW, Pechous PA, Spaethe SM, Roman CR, Fleisch JH (1999) Pharmacologic actions of the second-generation Leukotriene B4 Receptor Antagonist LY293111: in vitro studies. J Pharmacol Exp Ther 288(1):286-294
8. Mommers JM, Van Tossum MM, Kooijmans-Otero ME, Parker FL, van de Kerkhof PC (2000) VML 295(LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis. Br J Dermatol 142(2):259-266
9. Evans DJ, Barnes PJ, Spaethe SM, van Alstyne EL, Mitchell MI, O'Connor BJ (1996) Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 51(12):1178-1173
10. Marshall M, Diaz HB, Brozinick J et al (2002) LY293111 inhibits tumor cell growth in vitro through an apparent PPARγ agonist activity. Proc Amer Assoc Cancer Res 43:957 (abstract 4741)
11. Vamecq J, Latruffe N (1999) Medical significance of peroxisome proliferator-activated receptors. Lancet 354:141-148
12. Koeffler HP (2003) Peroxisome proliferators-activated receptor γ and cancers. Clin Can Res 9:1-9
13. Hennig R, Ding X, Tong W, Witt RC, Jovanovic BD, Adrian TE (2004) Effect of LY293111 in combination with gemcitabine in colonic cancer. Cancer Letters 210:41-46
14. Ding X, Talamonti M, Bell R Jr, Adrian TE (2005) A novel anti-pancreatic cancer agent, LY293111. Anticancer Drugs 16(5):467-473
15. Zhang W, McQueen T, Schober W, Rassidakis G, Andreeff, M, Konopleva M (2005) Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia 19:1977-1984
16. Tong W-G, Ding X-Z, Hennig R, Witt RC, Standop J, Pour PM, Adrian TE (2002) Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cell. Clin Cancer Res 8:3232-3242
17. Schwartz GK, Weitzman A, O'Reilly E, Brail L, de Alwis DP, Cleverly A, Barile-Thiem B, Vinciguerra V, Budman DR (2005) Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors. J Clin Oncol 23(23):5365-5373
18. Rosen LS (1998) Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology suppl 6:103-109
19. Budman DR, Calabro A (2004) Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111. Anti-Cancer Drugs 15(9):877-881
20. Armand JP, Extra YM, Catimel G, Abigerges D, Marty M, Clavel M (1996) Rationale for the dosage and schedule of CPT-11(irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 7(8):837-842
21. Therasse P, Arbuck SG, Eisenhauer EA, Wander J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 92:205-216
22. Abigerges D, Chabot GG, Armand J-P, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13(1):210-221.
23. Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Albers SA, Schaaf LJ, Elfring G, Miller LL (2000) Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 6(6):2236-2244